Literature DB >> 30196325

Treatment course and outcomes after revascularization surgery for moyamoya disease in adults.

Amanda Kahn1, Gurmeen Kaur2, Laura Stein2, Stanley Tuhrim2, Mandip S Dhamoon3.   

Abstract

BACKGROUND: International trials suggest benefit of revascularization surgery (RS) for moyamoya disease (MMD). However, nationally representative US data on demographics and outcomes after RS in MMD are lacking. AIMS: To estimate causes and rates of readmission after RS for MMD.
METHODS: In the Nationwide Readmissions Database, index admissions for ECICB for MMD and readmissions for ischemic stroke (IS), subarachnoid hemorrhage (SAH), and intracerebral hemorrhage (ICH) were identified using validated International Classification of Diseases, Ninth Revision, Clinical Modification codes. We summarized demographics and comorbidities, and calculated 30-, 60-, and 90-day readmission rates per 100,000 index admissions.
RESULTS: Among 201 index admissions for RS for MMD, mean age (SD) was 41.7 (12.6) years; 75% were female; 24% had diabetes; 53% had hypertension; 40% had hypercholesterolemia; 3% had ICH; 16% had IS; and 1% had SAH. RS was performed at large hospitals in 83%, urban hospitals in 85%, and teaching hospitals in 97%. 80% were discharged home. 34% had a readmission during follow-up. Leading reasons for readmission up to 90 days included MMD (62%), postoperative infection (10%), sickle cell crisis (4%), ischemic stroke (4%), epilepsy (2%), subdural hemorrhage (2%) and headache (2%). Readmission rates (per 100,000 index admissions) were 559 at 30 days, 1829 at 60 days, and 2027 at 90 days for IS. There were no readmissions for SAH or ICH.
CONCLUSIONS: This analysis of nationally representative US data suggests that although readmission after RS for MMD is not uncommon, cerebral hemorrhagic events during the 90-day postoperative period are rare.

Entities:  

Keywords:  Moyamoya disease; Stroke; Utilization

Mesh:

Year:  2018        PMID: 30196325     DOI: 10.1007/s00415-018-9044-z

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  26 in total

Review 1.  How to measure comorbidity. a critical review of available methods.

Authors:  Vincent de Groot; Heleen Beckerman; Gustaaf J Lankhorst; Lex M Bouter
Journal:  J Clin Epidemiol       Date:  2003-03       Impact factor: 6.437

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

3.  Lessons learned from moyamoya disease: outcome of direct/indirect revascularization surgery for 150 affected hemispheres.

Authors:  Miki Fujimura; Teiji Tominaga
Journal:  Neurol Med Chir (Tokyo)       Date:  2012       Impact factor: 1.742

4.  Moyamoya disease in China: its clinical features and outcomes.

Authors:  Lian Duan; Xiang-Yang Bao; Wei-Zhong Yang; Wan-Chao Shi; De-Sheng Li; Zheng-Shan Zhang; Rui Zong; Cong Han; Feng Zhao; Jie Feng
Journal:  Stroke       Date:  2011-10-20       Impact factor: 7.914

5.  Use of the All Patient Refined-Diagnosis Related Group (APR-DRG) Risk of Mortality Score as a Severity Adjustor in the Medical ICU.

Authors:  Daniel Baram; Feroza Daroowalla; Ruel Garcia; Guangxiang Zhang; John J Chen; Erin Healy; Syed Ali Riaz; Paul Richman
Journal:  Clin Med Circ Respirat Pulm Med       Date:  2008-04-18

6.  Epidemiological and clinical features of moyamoya disease in the USA.

Authors:  Daraspreet Kainth; Saqib A Chaudhry; Hunar Kainth; Fareed K Suri; Adnan I Qureshi
Journal:  Neuroepidemiology       Date:  2013-02-23       Impact factor: 3.282

7.  Stroke prevention by direct revascularization for patients with adult-onset moyamoya disease presenting with ischemia.

Authors:  Tackeun Kim; Chang Wan Oh; O-Ki Kwon; Gyojun Hwang; Jeong Eun Kim; Hyun-Seung Kang; Won-Sang Cho; Jae Seung Bang
Journal:  J Neurosurg       Date:  2015-12-04       Impact factor: 5.115

8.  Treatment of moyamoya disease with STA-MCA anastomosis.

Authors:  J Karasawa; H Kikuchi; S Furuse; J Kawamura; T Sakaki
Journal:  J Neurosurg       Date:  1978-11       Impact factor: 5.115

9.  Clinical outcome after 450 revascularization procedures for moyamoya disease. Clinical article.

Authors:  Raphael Guzman; Marco Lee; Achal Achrol; Teresa Bell-Stephens; Michael Kelly; Huy M Do; Michael P Marks; Gary K Steinberg
Journal:  J Neurosurg       Date:  2009-11       Impact factor: 5.115

10.  Proposal for a Prospective Registry for Moyamoya Disease in Japan.

Authors:  Ken Kazumata; Masaki Ito; Haruto Uchino; Hiroshi Nishihara; Kiyohiro Houkin
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-01-06       Impact factor: 1.742

View more
  2 in total

1.  Annual incidences and predictors of 30-day readmissions following spontaneous intracerebral hemorrhage from 2010 to 2014 in the United States: A retrospective Nationwide analysis.

Authors:  Haydn Hoffman; Taylor Furst; Muhammad S Jalal; Lawrence S Chin
Journal:  Heliyon       Date:  2019-12-27

Review 2.  Western Moyamoya Phenotype: A Scoping Review.

Authors:  Raphael Miller; Santiago R Unda; Ryan Holland; David J Altschul
Journal:  Cureus       Date:  2021-11-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.